Ceterix Orthopaedics announced the issuance of a new patent adding to the company's existing patent portfolio.
The new patent further protects the company's products and methods, such as its NovoStitch suture passer, which is used in the repair of meniscal tears and other soft-tissue joint injuries. The NovoStitch technology can also be used in minimally invasive hip and shoulder procedures.
"This patent adds to our robust intellectual property portfolio with more than 160 issued claims now protecting our approach," said John McCutcheon, president and CEO of Ceterix. "These patents are a testament to the innovative nature of our NovoStitch technology now in use at more than 200 centers in the U.S."
More articles on devices:
Medtronic CEO gets $24.8M reimbursement to cover tax inversion bill
Aurora Spine names Mike Coupland UK sales manager
8 factors making Zimmer's stock desirable in the future